ArGEN-X Concludes EUR 12.5 Million Series A Financing Round
ROTTERDAM, The Netherlands, December 3 /PRNewswire/ -- arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM)…